- Frozen (CL102) $ 1,250
Cell type: Fibrosarcoma
Transgenes: Human sodium iodide symporter (hNIS) with puromycin resistance (Puro) for selection with puromycin
Media: DMEM, 10% FBS, 1% Pen/Strep, 1 μg/mL puromycin
HT1080-hNIS-Neo/iRFP-Puro is a polyclonal population derived from the fibrosarcoma cell line HT1080 (ATCC® CCL-121™) transduced with a lentiviral vector LV-hNIS-Puro (LV019) encoding the human sodium iodide symporter (hNIS) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the puromycin resistance gene (Puro) via a P2A cleavage peptide.
The lentiviral vectors used are self-inactivating (SIN) vectors in which the viral enhancer and promoter has been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR (Miyoshi et al., J Virol. 1998).
HT1080-hNIS-Puro cell line has been tested for mycoplasma contamination and is certified mycoplasma free.
Cell Line Authentication:
The parental HT1080 cell line was authenticated are certified free of interspecies cross-contamination by short tandem repeat (STR) profiling with 9 STR loci including CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX, vWA and sex chromosome marker Amelogenin.
In vitro: This is a high NIS expressing cell line suitable for use as a positive control cell line in an iodine uptake assay to verify NIS expression in your lentiviral transduced cells.
In vivo: HT1080 cells form tumors post implantation into immunosuppressed mice. The in vivo growth of these tumors can be monitored using noninvasive, high-resolution 3D PET or SPECT imaging.
Morphology: Low- and high-density cell morphology (200x)
NIS Function Assay (Iodine Uptake): Cells were incubated with I-125 for 1h in the presence or absence of KClO4, an inhibitor of NIS mediated iodine uptake. Radioiodine concentrated within the cells was measured with a gamma counter.
References on NIS imaging:
1. Fruthwirth et al. A whole body dual modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment responses in different. microenvironments. J. Nucl. Med 2014. 55(4): 686-94.
2. Penheiter et al. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral and cell-based therapies. Curr Gene Ther. 2012, 12(1):33-47.